Title	**Integration of Liquid Biopsy into Lung Cancer Diagnostic Pathway**
Organisations Involved	Amgen Limited and All Wales Medical Genomics Service (Cardiff & Vale University Health Board)
Collaborative Working Project Description	This collaborative working project seeks to bring together stakeholders from industry and NHS Wales to transform current approaches to lung cancer care in Wales by expediting the clinical implementation of diagnostic ctDNA testing early in the diagnostic pathway. The overall aim of the Project is to reduce the Time to Treatment (TTT) of targeted therapies, resulting in improved outcomes for cancer patients. The intended aims of the Project are to: i. Establish RWE comparing the ctDNA vs tissue biopsies ii. Change the pathway to using ctDNA in its practice at one pilot center iii. Scale to additional centres within lung cancer (~740 patients) to provide evidence for routine commissioning across Wales. This experiment can lay the foundation for expansion to other tumor types.
Expected Outcomes	It is anticipated that the following benefits will be achieved throughout the lifecycle of the project: i. Patients: Rapid, less invasive diagnostics that result in more appropriate treatment options, improve outcomes and avoid potentially risky repeat biopsy procedures ii. NHS: More comprehensive and timely information at Multi-Disciplinary Team (MDT) that lead to more informed, rapid treatment decisions, fewer healthcare resources utilized and improved capacity and efficiency. The ability to scale nationally and best practice sharing across health boards can reduce care variation and inequalities. iii. Amgen: Patients will have access to more rapid testing for appropriate biomarker-directed therapies. Collaborative working with the consortium will demonstrate value as partner of choice with national organisation creating reputational benefits and invaluable insights into national cancer pathological and genomics pathways